Incorporating Heterogeneity Correction and 4DCT in Lung Stereotactic Body Radiation Therapy (SBRT): The Effect on Target Coverage, Organ-At-Risk Doses, and Dose Conformity

Abstract

This study evaluates the dosimetric impact of 4-dimensional computed tomography (4DCT) target volumes and heterogeneity correction (HC) on target coverage, organ-at-risk (OAR) doses, and dose conformity in lung stereotactic body radiation therapy (SBRT). Twelve patients with lung cancer, scanned using both helical CT and 4DCT, were treated with SBRT (60 Gy in 3 fractions). The clinical plans were calculated without HC and based on targets from the free-breathing helical CT scan (PTV HEL). Retrospectively, the clinical plans were recalculated with HC and were evaluated based on targets from 4DCT datasets (PTV 4D) accounting for patient-specific target motion. The PTV 4D was greater than PTV HEL when tumor motion exceeded 7.5 mm (vector). There were significant decreases in target coverage (V100) for the recalculated vs. clinical plans (0.84 vs. 0.94, p < 0.02) for the same monitor units. When the recalculated plans were optimized for equivalent V100 of the clinical plans, there were significant increases in the 60-Gy dose spillage (1.27 vs. 1.13, p < 0.001) and 30-Gy dose spillage (5.20 vs. 3.73, p < 0.001) vs. the clinical plans. There was a significant increase ( p < 0.04) in the mean OAR doses between the optimized re-calculated and the clinical plan. Tumor motion is an important consideration for target volumes defined using helical CT. Lower prescription doses may be required when prospectively planning with HC to achieve a similar level of toxicity and dose spillage as expected when planning based on homogeneous dose calculations.